Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab/Tuvorlimab (QL1706) with Modified TPF for Nasopharyngeal Carcinoma
NCT07085234Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in nasopharyngeal carcinoma (NPC), sponsored by First Affiliated Hospital of Xiamen University. Started Jul 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07085234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085234.